EKF Diagnostics Holdings plc
("EKF" or the "Company")
Result of AGM and Voting Results
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at it's Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:
|
| For | Against | Withheld | ||
| Resolution | Votes | % | Votes | % | Votes |
| 1 | 299,140,487 | 99.99% | 25,430 | 0.01% | 12,000 |
| 2 | 299,164,209 | 100.00% | 1,708 | 0.00% | 12,000 |
| 3 | 296,684,235 | 99.17% | 2,481,682 | 0.83% | 12,000 |
| 4 | 277,821,196 | 92.87% | 21,344,721 | 7.13% | 12,000 |
| 5 | 299,127,062 | 99.99% | 38,855 | 0.01% | 12,000 |
| 6 | 298,964,519 | 99.95% | 158,855 | 0.05% | 54,543 |
| 7 | 283,417,147 | 94.75% | 15,704,227 | 5.25% | 56,543 |
| 8 | 239,170,516 | 93.84% | 15,704,227 | 6.16% | 44,303,174 |
| 9 | 242,369,025 | 99.97% | 72,261 | 0.03% | 56,736,631 |
| 10 | 290,020,135 | 96.94% | 9,145,782 | 3.06% | 12,000 |
| EKF Diagnostics Holdings plc | |||
| Julian Baines, Executive Chair / Marc Davies, CFO | Tel: +44 (0)29 2071 0570 | ||
| | | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
| Aubrey Powell / George Tzimas / Oliver Platts | | ||
| | | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 | ||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.